Standard

From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs : HDAC inhibitors in the race for healthy aging drugs. / McIntyre, Rebecca L.; Daniels, Eileen G.; Molenaars, Marte et al.

In: EMBO molecular medicine, Vol. 11, No. 9, e9854, 2019.

Research output: Contribution to journalReview articleAcademicpeer-review

Harvard

APA

Vancouver

Author

BibTeX

@article{e3a68c12e029457fbe81f3fa15795dcc,
title = "From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs: HDAC inhibitors in the race for healthy aging drugs",
abstract = "Reversing or slowing the aging process brings great promise to treat or prevent age-related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for intervention. One component of epigenetic regulation involves histone deacetylases (HDAC), which include the “classical” histone deacetylases (of class I, II, and IV) and sirtuin deacetylases (of class III). While targeting sirtuins for healthy aging has been extensively reviewed elsewhere, this review focuses on pharmacologically inhibiting the classical HDACs to promote health and longevity. We describe the theories of how classical HDAC inhibitors may operate to increase lifespan, supported by studies in model organisms. Furthermore, we explore potential mechanisms of how HDAC inhibitors may have such a strong grasp on health and longevity, summarizing their links to other hallmarks of aging. Finally, we show the wide range of age-related preclinical disease models, ranging from neurodegeneration to heart disease, diabetes to sarcopenia, which show improvement upon HDAC inhibition.",
keywords = "Animals, Drug Evaluation, Preclinical, Epigenesis, Genetic, Healthy Aging/drug effects, Histone Deacetylase Inhibitors/administration & dosage, Histone Deacetylases/genetics, Humans, Longevity/drug effects",
author = "McIntyre, {Rebecca L.} and Daniels, {Eileen G.} and Marte Molenaars and Houtkooper, {Riekelt H.} and Janssens, {Georges E.}",
note = "{\textcopyright} 2019 The Authors. Published under the terms of the CC BY 4.0 license.",
year = "2019",
doi = "10.15252/emmm.201809854",
language = "English",
volume = "11",
journal = "EMBO molecular medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "9",

}

RIS

TY - JOUR

T1 - From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs

T2 - HDAC inhibitors in the race for healthy aging drugs

AU - McIntyre, Rebecca L.

AU - Daniels, Eileen G.

AU - Molenaars, Marte

AU - Houtkooper, Riekelt H.

AU - Janssens, Georges E.

N1 - © 2019 The Authors. Published under the terms of the CC BY 4.0 license.

PY - 2019

Y1 - 2019

N2 - Reversing or slowing the aging process brings great promise to treat or prevent age-related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for intervention. One component of epigenetic regulation involves histone deacetylases (HDAC), which include the “classical” histone deacetylases (of class I, II, and IV) and sirtuin deacetylases (of class III). While targeting sirtuins for healthy aging has been extensively reviewed elsewhere, this review focuses on pharmacologically inhibiting the classical HDACs to promote health and longevity. We describe the theories of how classical HDAC inhibitors may operate to increase lifespan, supported by studies in model organisms. Furthermore, we explore potential mechanisms of how HDAC inhibitors may have such a strong grasp on health and longevity, summarizing their links to other hallmarks of aging. Finally, we show the wide range of age-related preclinical disease models, ranging from neurodegeneration to heart disease, diabetes to sarcopenia, which show improvement upon HDAC inhibition.

AB - Reversing or slowing the aging process brings great promise to treat or prevent age-related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for intervention. One component of epigenetic regulation involves histone deacetylases (HDAC), which include the “classical” histone deacetylases (of class I, II, and IV) and sirtuin deacetylases (of class III). While targeting sirtuins for healthy aging has been extensively reviewed elsewhere, this review focuses on pharmacologically inhibiting the classical HDACs to promote health and longevity. We describe the theories of how classical HDAC inhibitors may operate to increase lifespan, supported by studies in model organisms. Furthermore, we explore potential mechanisms of how HDAC inhibitors may have such a strong grasp on health and longevity, summarizing their links to other hallmarks of aging. Finally, we show the wide range of age-related preclinical disease models, ranging from neurodegeneration to heart disease, diabetes to sarcopenia, which show improvement upon HDAC inhibition.

KW - Animals

KW - Drug Evaluation, Preclinical

KW - Epigenesis, Genetic

KW - Healthy Aging/drug effects

KW - Histone Deacetylase Inhibitors/administration & dosage

KW - Histone Deacetylases/genetics

KW - Humans

KW - Longevity/drug effects

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85070091397&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31368626

U2 - 10.15252/emmm.201809854

DO - 10.15252/emmm.201809854

M3 - Review article

C2 - 31368626

VL - 11

JO - EMBO molecular medicine

JF - EMBO molecular medicine

SN - 1757-4676

IS - 9

M1 - e9854

ER -

ID: 6835614